Investors from ImmunityBio, Inc. Can Lead a Securities Fraud Lawsuit

ImmunityBio, Inc. Securities Fraud Opportunity for Investors

In a significant development, shareholders of ImmunityBio, Inc. (IBRX) who experienced financial losses due to the company's alleged misleading statements have been provided an opportunity to lead a class action lawsuit against the entity. This lawsuit, organized by the law firm Glancy Prongay Wolke & Rotter LLP, focuses on accusations of securities fraud that could affect many investors who believed in the company's optimistic projections.

Context of the Lawsuit

The lawsuit primarily stems from allegations that between January 19, 2026, and March 24, 2026, ImmunityBio's management, namely Defendant Soon-Shiong, significantly overstated the capabilities of Anktiva, a product of the company. As a result of these representations, the defendants’ assertions about the business's health, operational efficacy, and future prospects have been deemed materially misleading. Many shareholders invested under the impression that they were participating in a stable and promising venture, unaware of the true nature of the company’s situation.

This class action lawsuit may provide a path for recovery for investors who feel wronged by the misleading portrayals by ImmunityBio. By joining this initiative, affected shareholders not only seek restitution but also aim to hold accountable those responsible for the alleged fabrications.

Who Can Participate?

The law firm has invited all investors who suffered losses related to their investments in ImmunityBio to join the lawsuit. Particularly, it’s important for those wishing to participate to note that the deadline to step forward as a lead plaintiff is set for May 26, 2026. Individuals interested in joining must promptly reach out to the law firm managing the case to express their intent to participate.

Steps to Get Involved

If you believe you qualify to join this class action lawsuit or simply want to learn more about your rights in these proceedings, you are encouraged to contact Glancy Prongay Wolke & Rotter LLP. The law firm is equipped to provide detailed information on the filing process and what actions you might need to take.

Contact Details

You can reach the law firm at:
Charles Linehan, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)

The law firm has assured that to be part of the class action, no immediate action is necessary; investors can retain their legal counsel or remain as absent members without any obligation.

Conclusion

This opportunity represents a crucial moment for numerous investors who feel betrayed by ImmunityBio's conduct. The class action lawsuit not only serves to provide potential financial restitution for the losses suffered but also highlights the need for transparency and accountability in the corporate sector. Stakeholders are encouraged to take swift action to protect their interests and participate in this pivotal legal remedy.